404922-72-1

Usage

Uses

Used in Pharmaceutical Industry:
(5-CHLORO-2-(1H-1,2,4-TRIAZOL-1-YL)PHENYL)METHANAMINE is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new medications and therapeutic agents.
Used in Agricultural Chemicals Industry:
(5-CHLORO-2-(1H-1,2,4-TRIAZOL-1-YL)PHENYL)METHANAMINE is used as a chemical intermediate in the production of agricultural chemicals, specifically in the synthesis of fungicides and antifungal agents, due to its ability to inhibit the growth of fungi and microorganisms.
Used in Materials Science:
(5-CHLORO-2-(1H-1,2,4-TRIAZOL-1-YL)PHENYL)METHANAMINE may have potential applications in materials science, where it can be utilized in the development of new materials with specific properties, such as enhanced stability or reactivity.
Used in Organic Synthesis:
(5-CHLORO-2-(1H-1,2,4-TRIAZOL-1-YL)PHENYL)METHANAMINE is used as a versatile chemical intermediate in organic synthesis, enabling the creation of a wide range of organic compounds for various applications, including pharmaceuticals, agrochemicals, and other specialty chemicals.

Upstream product

• 449758-31-0 5-Chloro-2-(1H-1,2,4-triazol-1-yl)benzonitrile 
• 21663-61-6 2,5-dichlorobenzonitrile 

Downstream Products

• 911831-64-6 N-[5-chloro-2-(1H-1,2,4-triazol-1-yl)benzyl]-1-(tert-butoxycarbonyl)-L-prolinamide 
• 1285539-11-8 C₂₆H₃₂ClN₅O₂ 
• 1002110-03-3 N-[5-Chloro-2-(1H-1,2,4-triazol-1-yl)benzyl]-2-[2-(1H-pyrazol-1-yl)ethyl]-2H-indazole-6-carboxamide 
• 1002110-35-1 N-[5-Chloro-2-(1H-1,2,4-triazol-1-yl)benzyl]-2-(2-ethylbutyl)-2H-indazole-6-carboxamide 

Relevant academic research and scientific papers

DPP-IV INHIBITORS

The invention relates to compounds of formula (I), Z-C(R1R 2)-C(R3NH2)-C(R4R5)-X-N(R 6R7), wherein Z, R1-7 and X have the meaning as cited in the description and the claims. Said compounds are useful as DPP-lV inhibitors. The invention also relates to the

Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors

In an effort to discover potent, clinically useful thrombin inhibitors, a rapid analogue synthetic approach was used to explore the P1 region. Various benzylamines were coupled to a pyridine/pyrazinone P2-P 3 template. One compound with an o-thiadiazole benzylic substitution was found to have a thrombin Ki of 0.84 nM. A study of ortho-substituted five-membered-ring heterocycles was undertaken and subsequently demonstrated that the o-triazole and tetrazole rings were optimal. Combination of these potent P1 aryl heterocycles with a variety of P2-P3 groups produced a compound with an extraordinary thrombin inhibitory activity of 1.4 pM. It is hoped that this potency enhancement in P1 will allow for more diversification in the P 2-P3 region to ultimately address additional pharmacological concerns.

Thrombin inhibitors

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: wherein R1 is, for example, hydrogen, Cl, or cyano, and R2 is, for example, hydrogen,

Thrombin inhibitors

Compounds of the invention are useful in inhibiting thrombin and treating blood coagulation and cardiovascular disorders and have the following structure: wherein R3 is hydrogen or halogen, and u is N or CH.